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In this article, we give an overview of new technologies for the diagnosis of tuberculosis (TB) and drug resistance,
consider their advantages over existing methodologies, broad issues of cost, cost-effectiveness and programmatic
implementation, and their clinical as well as public health impact, focusing on the industrialized world. Molecular
nucleic-acid amplification diagnostic systems have high specificity for TB diagnosis (and rifampicin resistance) but
sensitivity for TB detection is more variable. Nevertheless, it is possible to diagnose TB and rifampicin resistance
within a day and commercial automated systems make this possible with minimal training. Although studies are
limited, these systems appear to be cost-effective. Most of these tools are of value clinically and for public health
use. For example, whole genome sequencing of Mycobacterium tuberculosis offers a powerful new approach to the
identification of drug resistance and to map transmission at a community and population level.
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In 2011, 8.7 million people suffered from active tubercu-
losis (TB) with 1.4 million deaths, with over 95% of these
deaths occurring in low- and middle-income countries.
TB is also a major killer of those co-infected with hu-
man immunodeficiency virus (HIV), causing one quarter
of all deaths [1]. TB continues to be a significant public
health and clinical problem in the industrialized world.
Within countries of the World Health Organization
(WHO) European Region those in the East have much
higher notification rates than in the West. The Region
reported 309,648 new episodes of TB (34.0 per 100,000
people) with more than 60,000 deaths estimated as being
due to TB, or 6.7 cases per 100,000 people [2]. Notifica-
tion rates for newly-detected and relapsed TB cases in* Correspondence: f.drobniewski@qmul.ac.uk
1Public Health England National Mycobacterium Reference Laboratory, 2
Newark Street, London E1 2AT, UK
2Queen Mary University of London, 2 Newark Street, London E1 2AT, UK
Full list of author information is available at the end of the article
© 2013 Drobniewski et al.; licensee BioMed Ce
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumthe WHO 18 High Priority Countries (all from the cen-
tral and eastern part of the European Region), remained al-
most eight times higher (68.5 per 100,000 people) than in
the rest of the Region (8.4 per 100,000) [2].
Combination drug therapy has been the mainstay of
TB treatment for decades and six-month short-course
rifampicin-based regimens will cure almost all cases.
However, interrupted and incomplete therapy selects for
drug resistant strains, which are more difficult to treat
successfully. Multidrug-resistant tuberculosis (MDR-TB)
is caused by bacteria resistant to, at least, isoniazid and
rifampicin, two key first-line anti-TB drugs. Although
treatable with second-line drugs, therapy is less effective,
more toxic and prolonged, requiring up to two years of
treatment. Further resistance can develop to form exten-
sively drug-resistant TB, (XDR-TB), that is, MDR-TB
strains resistant to any fluroquinolone and amikacin or
capreomycin or kanamycin. Strains effectively resistant
to all available drugs have emerged.
There were an estimated 310,000 cases of MDR-TB
among notified TB patients with pulmonary TB in thentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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ring in India, China, and the Russian Federation and
Former Soviet States, including the Baltic countries [3].
Extensive travel and migration facilitates transmission of
resistant strains even to the countries of Western and
Central Europe where the rates of drug resistance re-
main low.
Exciting new advances in TB diagnostics offer the
hope of earlier diagnosis, increased cure rates and
greater public health benefit by reducing disease trans-
mission. For a long time, laboratories were neglected
and considered unimportant in the non-industrialized
world with an over-emphasis on the importance of
simple microscopy for case diagnosis. In middle- and
high-income countries, development continued with in-
novations in microscopy (for example, light emitting
diode (LED) microscopes), microbiological culture (for ex-
ample, rapid automated liquid culture systems, like the
Becton Dickinson MGIT 960 (Becton Dickinson, Sparks,
Maryland, USA), nucleic acid amplification systems (for
example, Hain Lifesciences (Nehren, Germany) line probe
assays and automated systems, such as the Cepheid
XpertW MTB/RIF system (Cepheid, Inc., Sunnyvale,
CA, USA).
Although there are point of care (POC) diagnostic
tests under development, accurate diagnosis of TB and
drug resistant TB requires some form of laboratory in-
frastructure (ranging from a simple light microscope to
molecular diagnostic instruments and/or multi-room la-
boratory suites to complex biosafety facilities for hand-
ling manual and automated liquid culture.
This article gives an overview of new technologies for
TB detection as well as drug resistance (including MDR-
TB and XDR-TB), focusing on immunocompetent
patients in the industrialized world. The role of new
diagnostics for TB detection in HIV co-infected individ-
uals and low income countries has been described else-
where [4-6].
New microscopy
Light microscopy (LM) of sputa has been the bedrock of
TB laboratory diagnosis for decades. It utilizes cheap
equipment and materials but is insensitive, non-specific,
(especially in the context of industrialized countries
where non-TB mycobacterial infections are more com-
mon), and requires patient, time-consuming observation
of slides. Fluorescent microscopy (FM) is superior in
that it is more sensitive than LM, and has a higher
throughput, but the equipment and bulbs are expensive
[7,8].
Advances in physics led to the development of light
emitting diodes (LED), with appropriate fluorescent light
output coupled with low power consumption, creating
cheaper robust LED FM microscopes, requiring minimalmains or battery power. The WHO has recommended
rolling out LED microscopes in lower income settings
where they offer the throughput and sensitivity of more
expensive fluorescent microscopes and are, therefore, of
benefit in high HIV prevalence environments where spu-
tum samples may carry a lower bacterial load; they can
also be used successfully in middle or higher income set-
tings [9,10].
For example, a multicenter study assessing the ease
and effectiveness of LED-based fluorescence microscopy
for TB detection (using PrimoStar iLED (Karl Zeiss,
Oberkochen, Germany) was conducted in the Samara
Region, Russia in 2008 and 2009 including two sites with
no prior experience in fluorescence microscopy (unpub-
lished data). The first phase (“ZN baseline”) aimed to
create a control group of Ziel-Nielsen (ZN) stained
slides to evaluate false positivity and negativity rates at
the demonstration sites. During the validation phase
both sites switched to LED-FM after training, followed
by implementation where all slides were stained by
auramine only. In this Russian study, the overall false
positivity and false negativity rates were 5.2% and 1.7%,
respectively. The false positive rates for each successive
phase were 9.2% (baseline introduction and comparison
with current Ziel-Nielsen staining), 4.5% (validation),
1.1% (implementation) and 1.0% (continuation); equiva-
lent false negative rates for each successive phase were
1.7% (baseline and comparison with current Ziel-Nielsen
staining), 2.4% (validation), 1.9% (implementation) and
0.9% (continuation). The proportions of false positive
and false negative results declined over the stages and
the proportion of major errors was almost negligible,
demonstrating that LED-FM can be easily implemented
in any TB laboratory even with limited prior staff experi-
ence. All participating microscopists demonstrated a
high level of satisfaction explained by the increased
speed of the examination and ease of use.
Novel molecular amplification test performance for TB
diagnosis
Rapid tools for TB detection developed over the last
decade in the industrialized world are largely Nucleic
Acid Amplification Tests (NAAT) based on amplifica-
tion of nucleic acids (DNA or RNA), often combined
with highly specific detection systems (hybridization
with specific oligonucleotide probes or alternatives) to
increase sensitivity and specificity of an assay. The
polymerase chain reaction (PCR) is the most common
methodology utilized in the NAAT; alternatives include
real-time PCR (RT-PCR), isothermal, strain displacement
or transcription-mediated amplification and ligase chain
reaction [11-15] (Table 1).
Speed and improved biosafety are the main advantages
of molecular assays: they only require high containment
Table 1 Commercially available NAAT assays for TB detection in clinical specimens*
Assay Manufacturer Method Material Sensitivity,%
(95% CI)
Specificity,%
(95% CI)
PLR NLR References
Amplified MTD Gen-Probe Inc., San Diego, CA,
USA
Transcription-mediated
amplification
DNA from
decontaminated
sputum
86.0
(74.2 to 93.7)
99.3
(96.3 to 100.0)
57.6
(25.5 to 129.9)
0.1
(0.07 to 0.22)
[11,16]
COBASW TaqManW MTB Test Roche Molecular Diagnostics,
Pleasanton, CA, USA
RT-PCR DNA from
decontaminated
sputum
91.5
(86.9 to 96.1)
98.7
(98.0 to 99.4)
- - [17,18]
79.1 98.2
artusW M. tuberculosis PCR Qiagen, Hilden, Germany RT-PCR DNA from
decontaminated
sputum
97.8
(93.6 to 95.5)
85.1
(75.8 to 91.8)
6.54
(4.0 to 10.8)
0.03
(0.01 to 0.08)
[19]
LoopampW Tuberculosis Complex
Detection Reagent Kit
EIKEN Chemical, Tokyo, Japan LAMP Untreated sputum 88.2
(81.4 to 92.7)
- - - [20]
Amplicor MTB Roche Molecular Diagnostics,
Pleasanton, CA, USA
PCR amplification of
16S RNA
DNA from
decontaminated
sputum
- - 26.04
(17.04 to 39.80)
0.15
(0.11 to 0.22)
[11]
Cobas Amplicor Roche Molecular Diagnostics,
Pleasanton, CA, USA
PCR amplification of
16S RNA
DNA from
decontaminated
sputum
- - 58.59
(37.77 to 90.86)
0.17
(0.13 to 0.22)
[11]
LCx Abbott Laboratories, USA,
Abbott Park, IL, USA
Ligase chain reaction DNA from
decontaminated
sputum
88.9
(82.5 to 96.3)
96.8
(95.1 to 98.5)
26.91
(17.21 to 42.09)
0.16
(0.12 to 0.20)
[11,21]
BD Probe Tec Direct Becton Dickinson, Sparks, MD,
USA
Strand Displacement
amplification
DNA from
decontaminated
sputum
77.5
(72.0 to 83.0)
98.0
(97.1 to 98.9)
20.11
(10.42 to 38.82)
0.06
(0.04 to 0.10)
[11,22]
XpertW MTB/RIF Cepheid Inc, Sunnyvale, CA,
USA
RT- PCR Smear-positive
sputum
98.0
(98.0 to 99.0)
99.0
(99.0 to 99.0)
[13,14,23-28]
XpertW MTB/RIF Cepheid Inc, Sunnyvale, CA,
USA
RT-PCR Smear-negative
sputum
75.0
(72.0 to 78.0)
99.0
(99.0 to 99.0)
[13,14,23-28]
*Sales of many of these commercial assays have now been discontinued.
NAAT, Nucleic acid amplification techniques; NLR, Negative likelihood ratio; PLR, Positive likelihood ratio.
D
robniew
skiet
al.BM
C
M
edicine
2013,11:190
Page
3
of
11
http://w
w
w
.biom
edcentral.com
/1741-7015/11/190
Drobniewski et al. BMC Medicine 2013, 11:190 Page 4 of 11
http://www.biomedcentral.com/1741-7015/11/190initially and can detect specific nucleotide sequences in
processed specimens (crude extracts or treated sputum)
within a few hours so the time for the TB detection can
be reduced to less than one day.
Although NAAT can theoretically detect a single
copy of nucleic acid in a specimen, their sensitivity
could be significantly compromised by the presence
of PCR inhibitors in clinical specimens and loss of
nucleic acids during processing of clinical specimens
and, therefore, tends to vary; specificity is usually
high (Tables 1 and 2) [11-13,17-20,22]. Recently,
line-probe assays (LPAs) and XpertW MTB/RIF
(Cepheid Inc.) have been formally endorsed by the
WHO and are now in routine use in many TB
laboratories in high- and middle-income countries.
Two LPAs currently available on the market for TB
detection in clinical specimens (INNO-LiPA Rif.TB
(Innogenetics, Zwijndrecht, Belgium) and GenotypeW
MTBDRplus (Hain Lifescience, GmbH, Nehren,
Germany) are based on the PCR of specific frag-
ments of the Mycobacterum tuberculosis genome
followed by hybridization of PCR products to oligo-
nucleotide probes immobilized on membranes.
As an example, one large national study in a non-
trial context conducted by Seoudi et al. [29] exam-
ined 7,836 consecutive patient samples over a decade
using INNO-LiPA Rif. TB and compared results with
a reference standard (conventional liquid and solid
media culture with rapid molecular identification and
culture-based drug resistance testing). For all sputum
specimens (n = 3,382), the sensitivity, specificity,
positive predictive value (PPV), negative predictive
value (NPV) and accuracy for M. tuberculosis com-
plex (MTBC) detection compared to reference micro-
biology were respectively 93.4%, 85.6%, 92.7%, 86.9%
and 90.7%; the equivalent values for smear-positive
sputum specimens (n = 2,606) were 94.7%, 80.9%,
93.9%, 83.3% and 91.3%.
XpertW MTB/RIF is a fully automated RT-PCR-
based assay. Much of its increased sensitivity is due
to the high volume of sputum that is effectively sam-
pled and compared to other NAAT systems, which isTable 2 Commercially available LPAs for TB detection in clini
Assay Manufacturer Method Material
INNO-LiPA
Rif.TB
InnoGenetics, Gent,
Belgium
PCR amplification/
hybridization
DNA from
smear-po
INNO-LiPA
Rif.TB
InnoGenetics, Gent,
Belgium
PCR amplification/
hybridization
DNA from
smear-ne
Hain GT
MTBDRplus
Hain Lifescience GbmH,
Nehren, Germany
PCR amplification/
hybridization
DNA from
sputum
CI, confidence interval; LPA, line-probe assay.an important lesson to developers of the next gener-
ation of tests.
Diagnosing TB and drug resistance simultaneously
While there have been accurate solid-media-based
microbiological tests for drug resistance for decades, the
use of commercial (for example, MGIT 960) [35,36] and
non- commercial liquid culture systems (for example,
microscopic observation drug susceptibility (MODS),
Thin Layer Agar (TLA) [37-41] from cultures or sputum
have facilitated more rapid diagnosis.
Encouragingly, in May 2009, the 62nd World Health
Assembly (WHA62.15) urged member states to take ac-
tion to achieve universal access to diagnosis and treat-
ment of M/XDR-TB by 2015.
However, real advances in the rapid (less than one to
two days) diagnosis of clinically-significant drug resist-
ance have been more recent, requiring identification of
mutations in genes responsible for resistance [42-46].
In 1998, an algorithm was proposed for a centralized
regional/national service using a combination of novel
amplification-based technology for rapidity, coupled
with automated liquid culture-based systems for sensi-
tivity of detection and first-line drug susceptibility [47].
The world’s first nationally-available service was established
in the UK in 1999.
Line probe assays
At that time, in-house and commercial LPAs were avail-
able which could detect TB and rifampicin (RMP) resist-
ance (as the overwhelming majority of resistance is
caused by mutations in a single gene, rpoB, the RNA-
dependent DNA polymerase). These assays rely on the
PCR-amplification of the region of interest followed by
binding to DNA probes bound to a solid membrane;
binding is detected colorimetrically, usually as visible
bands corresponding to the presence of TB and a sensi-
tive or resistant genotype. Currently, the main commer-
cial LPAs for the rapid diagnosis of TB (INNO-LiPA Rif.
TB (Innogenetics, Zwijndrecht, Belgium), GenoTypeW
MTBDR/MTBDRplus and Geno-TypeW MTBDRsl (both
Hain Lifescience), as well as the XpertW MTB/RIFcal specimens
Sensitivity,%
(95% CI)
Specificity,%
(95% CI)
References
decontaminated
sitive sputum
93.0
(92.0 to 94.0)
83.0
(81.0 to 85.0)
[29,30]
decontaminated
gative sputum
65.0
(58.0 to 71.0)
96.0
(94.0 to 97.0)
[29-32]
decontaminated 92.0
(90.0 to 94.0)
- [33,34]
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tion of resistance to rifampicin and (GenoTypeW
MTBDRplus only) isoniazid. These tests are designed for
use on M. tuberculosis isolates and/or primary respira-
tory specimens [11,29,31,32,48,49].
The GenoTypeW MTBDRsl is the only available rapid
assay for detection of resistance to fluorquinolones
(FQs), injectable second-line drugs (as well as etham-
butol (EMB)) and so offers a rapid detection of XDR-TB
in mycobacterial cultures [50,51].XpertW MTB/RIF
The XpertW MTB/RIF (Cepheid Inc.) is a fully auto-
mated RT-PCR- based assay for the detection of TB bac-
teria and resistance to RMP in clinical specimens [13,14]
and reviewed in [49] (also see Table 1). For TB diagnosis
in sputum smear-positive samples, studies showed sensi-
tivities ranging from 93% to 98% and specificities of 83%
to 99% [13,14,23-25].
For TB diagnosis, the overall sensitivity of RMP resist-
ance detection in patient specimens for the INNO-LiPA,
MTBDRplus and Xpert MTB/RIF assays was, respect-
ively, 93% (95% CI 89 to 96), 97% (95% CI 92 to 99) and
98% (95% CI 97 to 99), for the studies indicated. The
pooled specificity of INNO-LiPA, MTBDRplus and
Xpert was, respectively, 99% (95% CI 99 to 100), 98%
(95% CI 95 to 99) and 99% (95% CI 98 to 99)
[11,13,14,23-25,29,31,32,48,49].
The introduction of XpertW MTB/RIF-based diagnosis
increased TB case findings in India, South Africa and
Uganda compared to the use of simple microscopy and
clinical diagnosis from 72% to 85% to from 95% to 99%
of the cohort of individuals with suspected TB [52].
In the excellent WHO-led global roll-out document
for XpertW MTB/RIF [53], the key programmatic issues
for countries with a low prevalence of rifampicin resist-
ance (and MDR) TB is the low PPV of a positive resist-
ant result. This is the situation that applies in most
industrialized countries currently and means that most
“resistant” isolates will be false-positive ones. This neces-
sitates the use of a second, usually microbiological, test
to confirm resistance. The corollary is that the NPV is
good.Cost of new diagnostics
There have been limited studies on the cost and cost-
effectiveness of novel rapid tests and, in particular, the real
cost of the entire process (rather than simply the cost of
the material) and the overall clinical/diagnostic pathway,
which will influence the uptake.
As of 31 December 2012, a total of 966 XpertW MTB/
RIF instruments (5,017 modules) and 1,891,970 MTB/
RIF cartridges had been purchased in the public sectorin 77 of the 145 countries eligible for concessionary pri-
cing [54].
Pantoja et al. recently [55] assessed the cost, globally and
in 36 high-burden countries, of two strategies for diagnos-
ing TB and multidrug-resistant TB (MDR-TB): XpertW
MTB/RIF with follow-on diagnostics, and conventional
diagnostics. They showed that using XpertW MTB/RIF to
diagnose MDR-TB would cost US$0.09 billion/year glo-
bally and be of lower cost than conventional diagnostics
globally and in all high TB burden countries (HBCs). Diag-
nosing TB in HIV-positive people using XpertW MTB/RIF
would also cost about US$0.10 billion/year and be of lower
cost than conventional diagnostics globally and in 33 of 36
HBCs.
Testing everyone with TB signs and symptoms would
cost almost US$0.47 billion/year globally, much more
than conventional diagnostics. However, in European
countries, Brazil and South Africa the cost would repre-
sent <10% of overall TB funding. The authors concluded
that while using it to test everyone with TB signs and
symptoms would be affordable in several middle-income
countries, the financial viability in low-income countries
would require large increases in TB funding and/or fur-
ther price reductions.
Kirwan and colleagues [56] argued that studies on
XpertW MTB/RIF have shown cost-effectiveness in some
but not all settings. They pointed out that serial implemen-
tation of new technologies can cause ineffective spending
and fragmentation of services. The process by which new
tests are incorporated into existing diagnostic algorithms
would affect both outcomes and costs. They argue that
more detailed data on performance, patient-important out-
comes and costs when used with adjunct tests were needed
for each setting before implementation and that while
awaiting further clarification it would seem prudent to slow
implementation among resource-constrained tuberculosis
control programs [56].
Vassall et al. [52] showed that when XpertW MTB/RIF
was used as a screening tool for testing all TB suspects in
India, South Africa or Uganda, the cost and cost-
effectiveness increased from US$28 to US$49 from US
$133 to US$146, and US$137 to US$151 per TB case
detected if XpertW MTB/RIF is used “in addition to” and
“as a replacement of” smear microscopy.
Calculated incremental cost effectiveness ratios (ICERs)
for using XpertW MTB/RIF “in addition to” smear micros-
copy ranged from US$41 to $110 per disability adjusted life
year (DALY) averted and were below the WHO threshold
and, therefore, indicate XpertW MTB/RIF to be a cost-
effective method of TB diagnosis in low- and middle-
income settings. However, scale and range of current TB
diagnostic algorithm practice in other settings would deter-
mine the extent of the cost-effectiveness of adding this
new tool into routine practice [52].
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yield and cost-effectiveness will differ as microbiological
culture and/or DST will form the base case scenario.
Rapid diagnostics may have even greater financial impact
in identifying those patients with risk factors for MDR-
TB but who subsequently were shown to have simple
drug sensitive TB, that is, the shorter cost of enhanced
isolation facilities within institutions may justify the in-
creased diagnostic cost. For example, in one UK London
teaching hospital the use of line probe assays would have
created potential annual savings of between £50,000 and
£150,000 a decade ago [57].
There are no complete costs for the diagnosis and
management of TB which also include societal costs. A
review in 2007 calculated a UK annual drug bill of £1.95
million/year (2002 costs) [36]. The mean costs (includ-
ing in- and out-patient stay, drugs, toxicity monitoring)
of managing drug sensitive and MDR-TB cases in
London, UK were estimated to be approximately £6,000
and £60,000 in a study from 2000 [58]. In a more recent
German study, the costs were comparable with a mean
combined in-patient and out-patient costs of €7,364 and
to €52,259 for the treatment of a drug sensitive and
MDR-TB cases, respectively [59].
This is in broad agreement with a WHO report which
showed that the drug cost for treating drug-resistant pa-
tients was approximately 50 to 200 times higher than for
treating a drug-susceptible TB patient, with the overall
costs of care at least 10 times higher [3]. However, the
overall societal costs are more difficult to measure. In
the recent German study [59], 4,444 new cases of TB
were reported in 2009, with 2.1% (63 cases) MDR-TB
cases. The mean costs of treatment per TB case overall,
including treatment of MDR-TB, was €7,931 to which
was added the mean cost due to loss of productivity
(€2,313), costs per case for rehabilitation (€74) and con-
tact tracing (€922), giving a total of €11,240 as the over-
all societal cost. In a report from 2012 [60], the UK
reported 8,917 cases and 60 MDR-TB cases in 2009. As
the UK and German TB case management approaches
are broadly similar if we use the same societal cost
figure, then UK societal costs for TB are approximately
€100 million. The equivalent mean treatment cost would
be a little over €70 million.
There is a real need to model and cost end-to-end ser-
vices rather than perform simple analyses around the
cost of the diagnostic alone. It may be more cost effect-
ive in a high income, high cost environment to control
the whole process carefully for quality and to adjust
workflow. For example, the cost and cost-effectiveness
of the entire process in the UK will be influenced by
poor transport logistics. Alternative service delivery
models involving the leasing of vehicles with mobile
phlebotomist-technicians, for a blood sample-based test,who can either bring samples to the laboratory rapidly
for analysis, or perform a POC test on site may be more
cost-effective than the current practice.
Barriers to uptake
There has been a relatively slow uptake of new TB diag-
nostics, some of which have been available since the
1990s [47].
Within the UK health model, greater laboratory costs
should be offset against increased hospital (institutional)
savings to encourage innovation and reduce barriers to
adoption of newer tests by demonstrating rational cost
savings in place of simplistic percentage cost cuts used
currently. Other insurance-based health models, such as
those in France or Germany, are arguably better at
implementing proven diagnostics.
The underlying tension existing for all diagnostic tests
continues to be the debate over the merits of point of
care tests versus those performed in a more centralized
laboratory environment. Assuming the technical issues
are solved, arguably the greatest influence on whether it
is more cost-effective to bring samples to a laboratory or
use point of care tests, depends on transport logistics.
Public health relevance and impact of new diagnostics
Active TB
Any diagnostic tool may be of value clinically, for public
health or both. Clinically, we value a reduction in mor-
tality and modeling suggests a 100% sensitive and spe-
cific test with 100% access could prevent up to 36% of
TB related death [61]. Other models estimate that
employing more sensitive and rapid tests would produce
between a 17% and 23% mortality reduction [62,63].
However, a patient who survives but remains infec-
tious with TB, especially highly drug resistant TB, may
be of greater importance and danger from a public
health perspective. Globally, introduction of new diag-
nostics without anticipation and planning for an increase
in the number of cases diagnosed could lead to disaster
at the programmatic level as more patients are placed
on TB therapy, which then runs out; incomplete therapy
remains the overriding cause of clinically relevant drug
resistance [64-66]. Highly industrialized countries have
the financial ability to increase expenditure to compen-
sate for this increased treatment requirement at a pro-
grammatic level but there remains a need to understand
this need and plan for it.
Equally, diagnostic delay has led to failures in adopting
appropriate public health measures and has been docu-
mented in many high-income jurisdictions, for example,
in New York [67]. Patient and health service delays were
identified in a retrospective cohort study of patients with
pulmonary tuberculosis notified between 1 April 2001
and 1 March 2002 in London, UK. The median case
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patient-related delay was between 34.5 and 54 days and
the median health care-related delay was 29.5 days.
Shorter case finding delays were found in patients born
in a high prevalence country, patients presenting first to
an Accident and Emergency department (A&E), with
limitations in TB service capacity and organizational fac-
tors accounting for much of the delay [68].
These points and the potential effects of new versus
old procedures on public health efforts are summarized
in Table 3 and some of these are discussed in more de-
tail below. Clearly a rapid, highly specific and sensitive,
active TB test would be of equal clinical and public
health value. However, sputum smear microscopy has
been criticized because it is too insensitive and not spe-
cific enough for TB. Nevertheless, because of its relative
insensitivity, it is a good test of infectivity, identifying
those individuals with the highest bacterial load who are,
therefore, the most infectious and a priority for public
health intervention. Therefore, the urgent midnight spu-
tum smear examination may be of less clinical diagnostic
benefit but is essential to prioritize institutional and
community isolation procedures. A new POC diagnostic
test for TB, for example, with excellent specificity for
MTBC, but similar sensitivity to smear microscopy, may
be of limited clinical value but excellent public health
value helping to identify priority infectious cases and
limit transmission of TB further. For example, a study inTable 3 The impact of new diagnostic tools for TB on the pub
Initial versus new tool Use Staffing impact/
advantage
Patient impact/
advantage
TST versus gamma
interferon release
Latent TB Qualified nurse to
apply and read TST
vs phlebotomist
Two versus one v
infection
(LTBI)
Solid versus liquid
culture
Active TB Unchanged Improved sensitiv
Smear* versus XpertW
MTB/RIF system or LPA
Active TB Arguably less
trained staff
needed
Greater sensitivit
but no indicator
infectivity
Due to inactivation
lower risk of staff
infection
Smear *versus XpertW
MTB/RIF system or LPA,
for example, GenoTypeW
MDRTBPlus
Drug
resistance
Less qualified
personnel initially
for interpretation
Short turnaround
time for marker
antibiotic
Phenotypic versus
GenoTypeW MTBDRsl line
probe assay (LPA) for FQ,
injectable agents
Drug
resistance
Unchanged for
qualification of
staff, reduced risk
for staff infection
In areas with hig
MDR rates shorte
turnaround for X
TB detection
* “Smear” means the microscopic examination of sputum.
LPA, line prove assay; PPV, positive predictive value; MDR-TB, Multidrug-resistant tu
LTBI, Latent TB infection.South Africa attempted to use the cycle threshold values
of the Xpert system as a rule-in/rule-out test for smear
positivity and so infectivity; it had poor value as a rule-
in test but moderate value as a rule-out, although 20% of
individuals would have been erroneously ruled out as
smear negative [69].
An assay for drug resistance (for rifampicin, isoniazid
and MDR-TB) would be equally valuable for clinical
management and public health; correct therapy helps
the patients and, by rendering the individual non-
infectious, reduces disease transmission. However, there
is a further dimension in that by establishing the correct
level of isolation, disease transmission will be interrupted.
Tests for second line drug therapy, for example, to estab-
lish XDR-TB, are arguably of greater clinical value in that
the level of isolation and concern would have been
established by the MDR-TB diagnosis.
Such improvements in the speed and/or sensitivity of
diagnosis of TB and drug resistance have greatest poten-
tial impact on the clinical management of those co-
infected with HIV due to the high mortality associated
with MDRTB/XDRTB in middle or high income coun-
tries [70-74].
Latent TB infection (LTBI)
Although this review is focused on active TB, several in-
dustrialized countries are entering a phase of (potential)
TB eradication in their TB programs; in these states newlic health system
Laboratory
advantage
Reading Public health impact of
second tool
isit Low versus higher
specificity
Moderately
standardized
versus more
precise cut-off
Fewer referrals due to
more specific diagnosis
LTBI.
ity Higher sensitivity for
detection (but offset
if higher
contamination)
Non-
automated
versus
automated
cut-off
Identification of all TB
cases reduce transmission
y;
of
Low versus high
sensitivity and
specificity
Variable versus
cut-off
Fewer false positive results
No versus one key
marker antibiotic
(rifampicin) and also
isoniazid for LPA
Variable versus
exact cut-off
Immediate availability of
marker antibiotic results;
poor PPV in low
prevalence areas
h
r
DR-
Earlier XDR-TB screen
and set-up of other
drug testing for
treatment
Simpler cut-off;
limited drug
range
Immediate preliminary
screening for MDR- and
XDR-TB and aid planning
contact investigation
berculosis; TST, tuberculin skin testing; XDR-TB, extensively drug-resistant TB;
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indigenous population as it ages. Better identification of
truly latently-infected individuals offers the opportunity
to interrupt the onset of active (infectious) TB. Blood
tests based on Gamma-interferon release (IGRA) pro-
vide an improvement in specificity on classical tubercu-
lin skin testing (TST) as they are not influenced by prior
Bacillus Calmette–Guérin (BCG) vaccination [75-77].
Nevertheless, the value of IGRA tests clinically differs
from their public health value and both are dependent
on the willingness of well-feeling individuals to accept
and complete TB chemoprophylaxis, which is challen-
ging - both have value in identifying a significant expos-
ure in a contact investigation and in preventing further
harm, but they can also potentially provide wider pro-
grammatic understanding of undiagnosed TB transmis-
sion in a community. For example, in Baltimore, IGRA
implementation of LTBI evaluation in a public health
clinic significantly reduced the proportion of referred in-
dividuals with preliminary suspicion of LTBI diagnosis in
whom LTBI was finally diagnosed, but IGRA testing had
no impact on treatment initiation or completion [75].
Molecular epidemiological typing and Next Generation
Sequencing
This is a good example of new “diagnostic” techniques,
which are primarily of public health importance,
establishing unknown routes of disease transmission,
and confirming or refuting institutional outbreaks. Argu-
ably, the clinical value of these techniques is in primarily
identifying weaknesses in institutional infection control
procedures which lead to new TB cases and in
establishing the value of TB programmatic changes in
reducing transmission. For example, in a city, region or
country improvements in TB control through early diag-
nosis, effective treatment and improved infection, con-
trol may be masked by new migration of TB cases.
Techniques, such as variable number tandem repeat
(VNTR) [78] and next generation sequencing, may [79]
all be of value in establishing improvement by showing
that fewer TB cases were clustered together (clustering
indicating TB transmission between individuals). Re-
duced rates of TB case clustering together with data in-
dicating cure rates over 85% and reduced rates of drug
resistance development in cases which were initially
drug sensitive, provide a portfolio of indicators demon-
strating an effective TB program. In San Francisco, for
example, DNA fingerprinting showed a reduction in all
TB cases and clustered TB cases demonstrating an im-
provement in TB control [80-82].
Using whole genome sequencing and analyzing genetic
distance between isolates from pairs of household con-
tacts in the UK, Walker et al. [83] deduced that isolates
separated by less than five SNPs (single nucleotidepolymorphisms) were likely to be the result of recent
transmission events and that transmission could be ruled
out if isolates were separated by more than 12 SNPs. In
a similar study in The Netherlands, a low TB prevalence
country with robust procedures for contact tracing, 97
pairs of epidemiologically-linked isolates differed by an
average of 3.4 SNPs [84]. However, no epidemiological
link could be established between 82 pairs of isolates
that had no SNP differences.
Within a large, population sequencing study in the
Samara region of Russia, we established linkages be-
tween household contacts but for many clusters of TB
strains with no SNP differences, patients lived in
geographically-distant parts of the region making direct
transmission unlikely (data not shown). While cryptic
outbreaks may be uncovered in a low incidence setting
[83], the degree of relatedness between unlinked isolates
in high prevalence regions may make the establishment
of epidemiologic links between patients problematic.
Illustrating this, we found that when we applied whole-
genome sequencing to TB isolates from Estonia, col-
lected in 2008, they differed by only 16 SNPs from that
of a Lithuanian-born patient isolated in the UK in 2011,
and within the Beijing clade A in Samara, Russia, the
genetic distance between isolates belonging to a Latvian
and Russian patient was 13 SNPs. (data not shown).
None of these individuals could have been in direct con-
tact. However, a direct transmission link may be ruled
out based on a significant genetic distance between
isolates.
Furthermore, in low TB prevalence countries, where
one migrant population dominates a putative outbreak,
an understanding of the phylogeny of M. tuberculosis
in the patients’ country of origin may be critical to
correctly interpret genetic distances and surmise trans-
mission chains. Whole genome sequencing of M.
tuberculosis can offer a powerful new approach to the
identification of drug resistance and to map transmission
at a community and population level when carefully
interpreted.
Conclusions
Rapid diagnostics for TB and drug resistance have
undergone extraordinary development over the last dec-
ade with a major clinical impact on improving TB diag-
nosis and the early identification of drug resistant TB.
These improvements have led to more rapid implemen-
tation of the best therapy for given patients. There re-
mains a need for new diagnostics to improve the
sensitivity of detection for active TB in children, HIV co-
infected patients and extrapulmonary disease. The ideal
position should be akin to malaria diagnosis where ther-
apy is no longer automatically given when novel diag-
nostic tests are negative (ruled-out).
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industrialized world showed that early identification of
MDR-TB and the institution of therapy based on suscep-
tibility in laboratory drug-resistance assays led to
improved survival. The early and more accurate identifi-
cation of TB cases, drug resistance and institution of
appropriate therapy also removes sources of TB trans-
mission by curing them. This combination of rapid ac-
curate diagnosis and correct treatment is the root of all
successful TB programs and public health strategies. Re-
ducing diagnostic delay remains a high clinical and pub-
lic health priority.
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